AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03940638 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study NCT01843673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FBCT
Study NCT01843673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam computed tomography
Description: Undergo dual CBCT
Study NCT01843673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiography
Description: Undergo 2-D x-ray with Varian kV OBI
Study NCT01843673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiography
Description: Undergo 2-D x-ray with Brain Lab ExacTrac
Study NCT01843673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiography
Description: Undergo 2-D x-ray with Varian MV OBI
Study NCT01843673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electronic portal imaging
Description: Undergo EPID imaging
Study NCT01843673 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided adaptive radiation therapy
Description: Undergo IGART
Study NCT02321319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone HCl ER Tablets
Description: Hydromorphone hydrochloride (HCl) extended release tablet
Study NCT03186443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin was taken 300mg,q 12h for 6 month.
Study NCT03186443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin was taken 0.4, tid for 6 month.
Study NCT03676413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily inhalation throughout the study
Study NCT03790215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
Study NCT04148170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodiathermy Probe and Intubation Versus Intubation
Description: children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
Study NCT06029868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black seed oil capsule
Description: 700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,
Study NCT06029868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Black seed oil capsule
Description: Placebo Black seed oil capsule
Study NCT04452058 — intervention group
Intervention type: OTHER
Intervention: Radiomic Algorithm
Description: Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
Study NCT01805219 — intervention group
Intervention type: OTHER
Intervention: GPS and accelerometer recording (s) during exercises
Study NCT02894554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Study NCT02894554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamivudine
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Neoadjuvant treatment
Study NCT02708121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Intervention
Description: Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
Study NCT02708121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Intervention
Description: Participants informed that they have access to weight loss treatment.
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatine
Description: Neoadjuvant treatment
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Neoadjuvant treatment
Study NCT02919787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic surgery
Description: All patients
Study NCT02919787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic surgery
Description: All patients
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Adjuvant treatment
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Adjuvant treatment
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatine
Description: Adjuvant treatment
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatine
Description: Adjuvant treatment
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Adjuvant treatment
Study NCT02919787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Adjuvant treatment
Study NCT03986840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: A multicomponent exercise program
Study NCT03211611 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire given to the two groups
Description: Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP
Study NCT00582543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eMRI/MRSI
Description: Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
Study NCT02739386 — intervention group
Intervention type: BIOLOGICAL
Intervention: Ipilimumab
Description: Intravenous monoclonal antibody injection
Study NCT02668588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release of octreotide
Description: 1 intramuscular injection of extended release of octreotide 30 mg
Study NCT02668588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: extended release of placebo
Description: 1 intramuscular injection of extended release of placebo
Study NCT00927732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroquinidine
Description: capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
Study NCT00927732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (sugar)
Description: capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
Study NCT01005277 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04241315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38 for Injection
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Study NCT04241315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OTL38 for Injection
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Study NCT04241315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared camera imaging system
Description: Near infrared camera imaging system
Study NCT00872794 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy ASR™ Hip System
Description: A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
Study NCT03429010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New guideline anesthesia strategy team
Description: New guideline anesthesia strategy team
Study NCT03421795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Let's Talk About Pain Training
Description: See arm/group descriptions.
Study NCT03421795 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Family Centered Care Training
Description: See arm/group descriptions.
Study NCT00822627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
Study NCT00822627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and referral
Description: Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
Study NCT02301546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: computerized cognitive exercises
Description: Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
Study NCT03986840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: A multicomponent exercise program
Study NCT02301546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computerized cognitive exercises
Description: Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
Study NCT02346643 — intervention group
Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium Neurostimulator
Study NCT00066222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
Study NCT00066222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
Study NCT00066222 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
Study NCT01469143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
Study NCT01469143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
Study NCT04227795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-Assisted real time colonoscopy
Description: The colonoscopy was performed under artificial intelligence assistance
Study NCT06094361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iontophoresis Intervention
Description: Iontophoresis was applied with a Chattanooga Physio (DJO Global, Herentals, Belgium) brand device. The galvanic current mode was selected for the intervention. Intervention area was cleaned to prevent irritation and active electrode pad (cathode-5 cm2) was immersed in 75 mg diclofenac sodium solution. The current intensity of the application for 10 minutes was 0.1-0.2 mA/cm2.
Study NCT06094361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Phonophoresis was performed with a Chattanooga brand ultrasound device (Chattanooga, Intelect Legend Ultrasound, TN, USA). 75 mg gel containing 1% diclofenac sodium was applied to the shoulder area. The ultrasound was conducted continuously for 6 minutes with frequency of 1 MHz and an intensity of 1.5 watts/cm2.
Study NCT06094361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.
Study NCT01208883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: repetitive per-treatment [18F]FDG-PET for treatment adaptation
Description: repetitive per-treatment \[18F\]FDG-PET for treatment adaptation
Study NCT03455933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Comparator
Description: The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
Study NCT03455933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Intervention
Description: The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
Study NCT03455933 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
Study NCT00235235 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: core biopsy
Study NCT00235235 — intervention group
Intervention type: PROCEDURE
Intervention: Serum Collection
Description: serum collection
Study NCT00235235 — intervention group
Intervention type: PROCEDURE
Intervention: Urine Collection
Description: urine collection
Study NCT00235235 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
Study NCT00235235 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
Study NCT00235235 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
Study NCT00235235 — intervention group
Intervention type: DRUG
Intervention: Vinorelbine
Description: Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
Study NCT00235235 — intervention group
Intervention type: DRUG
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
Study NCT01188551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine (1 µg/kg) will be administered intranasally
Study NCT01188551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl (2 µg/kg) will be administered intranasally
Study NCT01188551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Sedative given pre-op.
Study NCT01188551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Sedative given pre-op.
Study NCT03743389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12G pigtail catheter
Description: 12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.
Study NCT03743389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 16F chest tube
Description: 16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
Study NCT01703091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT04020289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Program BalancingMySwing
Description: Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy
Study NCT04020289 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducational Program BalancingMySwing
Description: Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy
Study NCT01703091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT01703091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Administered IV
Study NCT01703091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV
Study NCT01933698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: Comparison of pharmacokinetics of both formulations
Study NCT00801073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human Amniotic Membrane Transplantation
Description: Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
Study NCT01296711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038 (olokizumab)
Description: 100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
Study NCT01748461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured intervention
Description: 3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
Study NCT01748461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coach intervention
Description: promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
Study NCT06264089 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preservation Rhinoplasty Nasal Valve Angle and Area
Description: The same group of patients who underwent Preservation Rhinoplasty will be followed and the nasal valve angles before and after surgery will be compared.
Study NCT01326884 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ZLP
Description: ZLP Graft
Study NCT00387569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MnB vaccine rLP8026
Description: MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
Study NCT00387569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MnB vaccine rLP8026
Description: MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
Study NCT00387569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MnB vaccine rLP8026
Description: MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
Study NCT00883168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00883168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastineHcl
Description: azelastine hydrochloride 548 mg
Study NCT00883168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 200 mcg
Study NCT00883168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastine Hcl/fluticasone propionate
Description: azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
Study NCT02502292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fotonovela
Description: Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet.
Study NCT03249909 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exufiber Ag+
Description: gelling fibre dressing with silver
Study NCT01221571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM 13
Description: Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
Study NCT01919125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 supplied as 50 mg tablets.